CRI Report: At present, as the largest vaccine consumer in the world, China possesses almost 40 vaccine manufacturing enterprises, which can produce 46 kinds of vaccines for preventing 27 kinds of diseases. China domestic vaccines are mainly traditional vaccines including monovalent vaccines, attenuated live vaccines, etc. In addition, foreign vaccines are mainly new-style vaccines including combined vaccines, inactivated vaccines, etc. China domestic vaccines still lag far behind international advanced levels in production capacity and key technologies.
The qualities of some China domestic vaccines are substandard and supervision departments lack system assessment on these vaccines after they come into the market on a large scale. Some China domestic vaccines lag far behind imported vaccines in quality, which are totally.
Some experts consider that the adverse reactions of vaccines are closely related to the current status in China, such as lagging technologies, poor qualities. China domestic Vaccine I market is basically monopolized by China National Biotec Group, which belongs to the six large Institute of Biological Products and Beijing Tiantan Biological Products Co., Ltd. These research institutions were directly subordinate to the government in the past. After marketed in 1987, they become state-owned enterprises, but they still have a stronger official color. In the bidding every year, leaders of the six large Institutes of Biological Products, the Ministry of Health and Disease Control and Prevention Center will hold a meeting to fix prices and arrange the production according to the orders. The aim is to avoid the internal competitions in prices and qualities through unifying the prices and managing by regions, so the phenomenon of selecting the superior and eliminating the inferior does not exists at all.
At present, there are new technologies in producing vaccines in China, which are also applied in other foreign countries. However, there are no policies and systems to promote the new technologies in China, so China still applies the old vaccine manufacturing technologies of 30 years ago with little update or even no update.
In China, Vaccine I is still attenuated live vaccines including polio vaccines, BCG vaccines, measles vaccines, encephalitis vaccines and so on, which was completely transformed into inactivated vaccines in foreign countries about ten years ago. There are still many difficulties in employing inactivated vaccine technologies to produce combined vaccines. As to single vaccines, there is definitely no problem in technologies to transform all the attenuated vaccines of Vaccine I into inactivated vaccines, but the largest problem is the cost. The government purchase price of Vaccine I is only CNY 1.8. However, if it is transformed into inactivated vaccines, the cost will increase by dozens of times.
Vaccine I is actually monopolized without any competition. To transform it into inactivated vaccines will need to update production lines and eliminate lagging production capacities. Only part of Vaccine II market is open. Although foreign companies occupy 50% market share of China Vaccine II market, the price of Vaccine II is too high due to the high tariff and various costs in administration and logistics. Only few consumers can afford Vaccine II, so it will not cause impact on Vaccine I market.
Vaccine II market is spotty, let alone the quality of Vaccine II. China National Biotec Group occupies over 60% market share of the whole vaccine market in China and basically controls the whole Vaccine I market. Other over thirty vaccine plants can only strive to get the less than 40% market share.